Eyenovia acquires exclusive U.S. rights to Formosa's APP13007 (clobetasol) for ocular surgery inflammation/pain

HYPERION DEFI, INC.

PDUFA action date for APP13007 (clobetasol) set for March 4, 2024.
Upfront payment of single-digit million in cash and stock; up to $4M in development and $80M in sales milestones.
APP13007 offers 2x/day dosing vs. standard 4x/day for post-surgical ocular inflammation/pain.
Eyenovia plans to develop clobetasol-Optejet for dry eye, a $3.6B U.S. market.
Product complements existing Mydcombi sales force; addresses >7M annual ocular surgeries.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

HYPERION DEFI, INC. entered into License Agreement with Formosa Pharmaceuticals, Inc. valued at $2 million within 45 days of the effective date of the agreement (effective 2023-08-15).

Action: entry
Agreement: license
Counterparty: Formosa Pharmaceuticals, Inc.
Value: $2 million within 45 days of the effective date of the agreement
Effective: 2023-08-15

Exact text from the filing

On August 15, 2023, Eyenovia, Inc. (the “Company”), entered into a license agreement (the “License Agreement”) with Formosa Pharmaceuticals, Inc. (“Formosa”).

View on SEC.gov

273 material agreements filed in the last 30 days. Browse all material agreements →

HYPERION DEFI, INC. filing history →

Source: SEC EDGAR

accession 0001104659-23-092219

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.